<DOC>
	<DOC>NCT00109564</DOC>
	<brief_summary>The purpose of this Phase II study is to evaluate the efficacy and safety of ispronicline (TC-1734-112) compared to placebo (inactive substance pill) in patients with age associated memory impairment (AAMI). AAMI is characterized as cognitive impairment including memory loss and poor concentration associated with aging.</brief_summary>
	<brief_title>A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI)</brief_title>
	<detailed_description />
	<mesh_term>Memory Disorders</mesh_term>
	<mesh_term>Nicotinic Agonists</mesh_term>
	<mesh_term>Acetylcholine</mesh_term>
	<criteria>Male or female subjects aged 5080 years. Lives with a significant other. Has subjective memory complaints. Verbal verification of this subjective memory complaint will be obtained from the significant other. Has no severe, uncontrolled medical condition. If receiving treatment for a medical condition, that treatment has been stable for at least 2 months before entering the trial and to remain stable throughout the trial. Exclusion Criteria Aged less than 50 years or greater than 80 years. Lives alone. Has any medical condition not adequately controlled, or likely to interfere with performance of the study procedures. Medication for a medical condition has been changed in the last 2 months or during the trial. Administration of acetylcholinesterase inhibitors and gingko biloba within 2 months prior to entering the study. Has evidence of depression or anxiety Meets DSMIV criteria for Alzheimer's or vascular dementia. Has participated in an investigational drug trial in the previous 30 days.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>AAMI</keyword>
	<keyword>Memory Impairment</keyword>
	<keyword>Decline in Cognitive Function</keyword>
	<keyword>Age Associated Memory Impairment</keyword>
</DOC>